Eli Lilly and Company (NYSE:LLY) Stock Price Down 1% – Here’s What Happened

Shares of Eli Lilly and Company (NYSE:LLY) dropped 1% during mid-day trading on Tuesday . The stock traded as low as $995.07 and last traded at $1,007.37. Approximately 2,837,315 shares changed hands during mid-day trading, a decline of 15% from the average daily volume of 3,354,156 shares. The stock had previously closed at $1,017.97.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: TRANSCEND‑T2D‑1 update signals progress for retatrutide, Lilly’s next‑generation obesity/T2D candidate — a successful Phase 3 program would materially expand Lilly’s weight‑loss franchise beyond tirzepatide. Eli Lilly’s TRANSCEND-T2D-1 Trial Completion
• Positive Sentiment: Abemaciclib combination moves deeper into advanced prostate cancer (Phase 1b expansion) — advances Lilly’s oncology pipeline and potential new indications for a marketed CDK4/6 asset. Eli Lilly’s Abemaciclib Combo
• Positive Sentiment: Lilly launched “Employer Connect” to help employers cover obesity medicines (including Zepbound/tirzepatide) with a $449 single‑patient sample option — a direct access push that should broaden uptake and address a major payer/employer barrier. Eli Lilly launches program to help boost employer coverage
• Positive Sentiment: Ventyx Biosciences shareholders approved a merger with Lilly — an M&A win that strengthens early‑stage oncology/technology capabilities. Ventyx Shareholders Approve Merger
• Positive Sentiment: Regulatory/regional expansion: EMA gave a positive opinion on Olumiant for alopecia (broadens immunology footprint) and Australia’s TGA is evaluating an oral GLP‑1 candidate — both support longer‑term revenue diversification. EMA Positive Olumiant Alopecia Opinion Oral GLP-1 Evaluated by TGA
• Neutral Sentiment: Analyst/media pieces highlight Lilly’s strong momentum and deep pipeline — positive narrative but already reflected in a high valuation; useful context for longer‑term holders. Why LLY Is a Strong Momentum Stock
• Negative Sentiment: Pricing pressure and competitive GLP‑1 dynamics remain a key tail risk — recent commentary points to a 5% share decline over a month driven by fears around pricing, affordability programs and intensifying rivalry, which can compress multiples even as sales grow. Lilly Stock Down 5% in a Month

Analyst Ratings Changes

Several equities analysts have recently commented on LLY shares. The Goldman Sachs Group set a $1,260.00 target price on shares of Eli Lilly and Company in a research report on Thursday, February 5th. National Bank Financial set a $1,286.00 price objective on Eli Lilly and Company in a research report on Monday, December 1st. Zacks Research downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Morgan Stanley reaffirmed an “overweight” rating and set a $1,313.00 target price on shares of Eli Lilly and Company in a research note on Thursday. Finally, Argus boosted their price target on Eli Lilly and Company from $930.00 to $1,200.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,229.59.

Eli Lilly and Company Trading Down 2.4%

The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. The firm’s 50-day moving average is $1,049.25 and its 200-day moving average is $936.91. The firm has a market cap of $923.62 billion, a price-to-earnings ratio of 42.66, a P/E/G ratio of 1.17 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period last year, the firm earned $5.32 earnings per share. The business’s quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is 30.15%.

Institutional Investors Weigh In On Eli Lilly and Company

Institutional investors have recently added to or reduced their stakes in the company. Norges Bank bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth $12,976,634,000. Laurel Wealth Advisors LLC grew its position in shares of Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after acquiring an additional 11,537,661 shares during the period. Capital Research Global Investors increased its stake in shares of Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after purchasing an additional 4,332,008 shares during the last quarter. J. Stern & Co. LLP raised its holdings in shares of Eli Lilly and Company by 46,191.3% in the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock worth $4,047,245,000 after purchasing an additional 4,038,502 shares during the period. Finally, Cardano Risk Management B.V. raised its holdings in shares of Eli Lilly and Company by 876.1% in the 4th quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock worth $2,552,419,000 after purchasing an additional 2,131,734 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.